Mirai Bio specializes in the development of genetic medicines, focusing on optimizing performance and accelerating the translation of these therapies from concept to clinical application. The company employs a generative design approach to create optimized cargo for potent and targeted genetic medicines. Their innovative platform is designed to enhance the delivery of genetic medicines to a wide range of tissues and cell types, overcoming the limitations of current delivery methods that are restricted to a narrow therapeutic window. By utilizing machine learning-derived lipids, Mirai has successfully unlocked access to previously inaccessible cell types, thereby broadening the potential applications of genetic therapies.

The company’s platform integrates several advanced methodologies, including high-throughput in vivo multiplexing, which allows for the simultaneous testing of thousands of formulations to identify the most effective therapeutic compositions. Additionally, Mirai emphasizes co-optimization of design, delivery, and manufacturing processes, utilizing extensive data optimization loops to refine each medicine's formulation and production strategy. This comprehensive approach positions Mirai as a leader in the genetic medicine field, enabling partnerships with innovators in genome engineering and cell therapy to expedite the development of transformative therapies.

United States

We're Mirai Bio, biotech's first open end-to-end development platform company for co-creation of optimized #GeneticMedicines. Learn more at MiraiBio.com.

Mirai Bio

Company Details